We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 590

Regulating the nip and tuck: cosmetic medical services growth expands
  • Maddocks
  • Australia
  • May 21 2015

Cosmetic medicine is one of Australia's fastest growing consumer markets, yet the AUD $1 billion1 consumer market is largely unregulated. On the


Food law: quick bites and upcoming calendar
  • King & Wood Mallesons
  • Australia
  • April 30 2015

The ACCC is seeking leave to appeal the Federal Court decision dismissing its case against Pfizer for alleged misuse of market power and exclusive


Traversing the patent cliff
  • DLA Piper LLP
  • Australia
  • April 29 2015

On 25 February 2015, the Federal Court handed down its much-anticipated judgment in the matter of ACCC v Pfizer Australia Pty Ltd. In dismissing the


ACCC takes action against health service providers
  • Lander & Rogers
  • Australia
  • April 10 2015

While claims for damages in tort and contract are common sources of liability for health service providers, recent actions by the Australian


ACCC v Pfizer some guidance to pharmaceutical companies on navigating competition risk
  • Herbert Smith Freehills LLP
  • Australia
  • March 3 2015

In brief The Federal Court of Australia has recently dismissed the ACCC’s case against pharmaceutical company Pfizer. The ACCC alleged that Pfizer had


ACCC v Pfizer some guidance to pharmaceutical companies on navigating competition risk
  • Herbert Smith Freehills LLP
  • Australia
  • March 3 2015

The Federal Court of Australia has recently dismissed the ACCC’s case against pharmaceutical company Pfizer. The ACCC alleged that Pfizer had misused


Federal government’s “action plan” for Australia will the direct selling sector be affected?
  • Addisons
  • Australia
  • December 2 2014

In November 2014 the Australia federal government released its Industry Innovation and Competitiveness Agenda (the Agenda), a report1 outlining the


Hospital’s by-laws flatline on the competition table
  • King & Wood Mallesons
  • Australia
  • December 22 2014

The ACCC has launched proceedings in the Federal Court against Little Company of Mary Health Ltd and its subsidiary Calvary Health Care Riverina Ltd


Pfizer case shows protecting your own position isn't anti-competitive
  • Clayton Utz
  • Australia
  • March 2 2015

Commercial strategies and practices used by Pfizer to counter the expected loss of revenue caused by the expiry of its patent over Lipitor, its


Harper Review - implications for the private health insurance industry
  • DLA Piper LLP
  • Australia
  • April 10 2015

On 31 March 2015 the final report of the Competition Policy Review Panel chaired by Professor Ian Harper (Harper Review) was released. The Harper